{"name":"Intercept Pharmaceuticals","slug":"intercept-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":130956000,"revenueGrowth":247.5,"grossMargin":0,"rdSpend":176639000,"netIncome":221816000,"cash":553711000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNSWF2WjRNVkU0eW5TS1Jwek1kQ3V2LUEtMjc4ZmpaMGxZanpoanNXSXd2aXNKRGFxbS1YaGJVREhNYUxmMWlTYThoTnFrcGtHQV8xaURaLW5UbmlCekFDYkNmLUh3SXNKdER4Y1h1TVFha2Z2TUFKOE1ZeG5EeXRIanF6anp0Qkg4bjdqdWRncldST1hHbkpCUWw0aHQ?oc=5","date":"2025-12-18","type":"pipeline","source":"Patch","summary":"Mass Layoffs At NJ Pharma Company After Liver Drug Linked To 19 Deaths - Patch","headline":"Mass Layoffs At NJ Pharma Company After Liver Drug Linked To 19 Deaths","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNbW1Oc0RWOVJEXy02OVhXUDlGY196VnBNTVhlTEY5bDMzX3VkSDY4dE5CTTlETVhQX1hONmdNWlFlSTN4SnFqem41dzNNOTBma3NnRThZV0Z2T0R0dG5TWEtOZzRQM3ZFSlc2NlJlRndjWVRtOG1tRGZXdzRsVmJEbXVTY1d3bThKaTJPWmU3RXVnUnk5Q05tZXlsdw?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Pharma","summary":"Intercept, on heels of Ocaliva withdrawal, restructures with 146 layoffs - Fierce Pharma","headline":"Intercept, on heels of Ocaliva withdrawal, restructures with 146 layoffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQOHN5alFhdDJpdjZUbFV1TnJPeHZObzBxd25XOTVLOEQ2c3BudUdLbDRDYzZYNlBCenhSTW9RVTBUSUY3RndOWng5aUExMHFNMkZUdVFWaXdoOTZtQURoS3lxSjFDS09aNDNrZVdyTFdIU3BOTktsd2NiclNROVJtcnRFaFJ2LUNiSGE0MG5nOWp3dw?oc=5","date":"2025-12-04","type":"pipeline","source":"Strauss Borrelli PLLC","summary":"Intercept Pharmaceuticals WARN Act Investigation - Strauss Borrelli PLLC","headline":"Intercept Pharmaceuticals WARN Act Investigation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQN2pQMGF0UlVpR3NDRkhXSm1iLVJUbkpDdmVXX2ZFYnRzRmUyWHlHaFhSWXdtSWd4TkpNOVJsOG13UzJsWTJJaTlVTHBCeURoREEtYnJ4VGZJODlaVk1XandUQXdCLU53a09LZmJ0RjJKNXZQMWg0MmIxRFFuZ1VMX05Wc0tPRmJkOG8yUm1RVGZQemNfbDZHSEJwbFp3LWhBZFBFYlV2LUFtNHNsTTNkYkRQMTY3SjAtYjhz?oc=5","date":"2025-09-12","type":"regulatory","source":"MedCity News","summary":"Long Regulatory Saga for Intercept Pharma Liver Drug Ends a Decade After Speedy FDA Approval - MedCity News","headline":"Long Regulatory Saga for Intercept Pharma Liver Drug Ends a Decade After Speedy FDA Approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPLThGdnJnZzhhSzgwUmx1X3piMUx6R1JuOVRTYy1ndlNiOXhMRTd3S28ydENPNkdZQnRhSDdBSzFhYkREN2JnZVhtTFZoRFUwVDZ3LUtkNU83blQ4UDN3aXUtc0lyVjJQWl8zbHZkb1lvY2k0TUVmSGYwVlJ6emE0TERycUNtMFFHb2NyYTdPNXB2eWpZQnA2OVZiVHc3TTVRVGFERERKNjNwVFV4aXZ3?oc=5","date":"2025-09-11","type":"pipeline","source":"Pharmaceutical Executive","summary":"Intercept Pharmaceuticals Withdraws Ocaliva from Shelves Following U.S. Regulator’s Request - Pharmaceutical Executive","headline":"Intercept Pharmaceuticals Withdraws Ocaliva from Shelves Following U.S. Regulator’s Request","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTFB5cTUxMG5QWTd4bDVKSk9vOENld2E0V3pzT3RRSDBseF9YazcwelVFQnpjYWdFc1RSTkpPR01pYm1veDhsdVlSbmc2Q3FPQU1RZDJnb1JueXRKcXRrMTA3OEdGQW9RckRZNl9HV25jNF8?oc=5","date":"2025-09-11","type":"pipeline","source":"pharmaphorum","summary":"Intercept pulls Ocaliva off the market in the US - pharmaphorum","headline":"Intercept pulls Ocaliva off the market in the US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFA4Nk9sdGlrbU1YSGNFaFowNUhaUGhMZzFMYkpnSThOV1gwdmRwNHNiT0M3d25vOFVYQm92bFc3VmFWZzhWOXRUVzI4a3NiaWR5ZUhj?oc=5","date":"2025-09-11","type":"regulatory","source":"FirstWord Pharma","summary":"Intercept pulls Ocaliva from US market after FDA request - FirstWord Pharma","headline":"Intercept pulls Ocaliva from US market after FDA request","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-11","type":"pipeline","source":"GlobeNewswire","summary":"Intercept Announces Voluntary Withdrawal of OCALIVA® for - GlobeNewswire","headline":"Intercept Announces Voluntary Withdrawal of OCALIVA® for","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNM3U5UUhUVmZVSnMtX2VHSkQ4S1AwazZ3NzFuWEhJalJldXRLMGw0eU8tT2tNdVBMemtxMC1EV0JWdWVYM1NTamZKTzY0WllhamY5bEtDX0NTX1BUSGJYSFlkM0k4bHVtcHNSU09DT1k4LUZJM2NlMlJ0ZkFFSXJ2ekhkM1FkdDFxUGtjRnZCTGl5ajdLSmFDczlYa3g5THd2cTVCTkxlVENFUmRxRlctbnFUVXUwb1pBR3FyelpSdGtFOGFhR2hDOWNlclBDck5ISnRGWjNNMk1JeEF0aTBJ?oc=5","date":"2025-09-11","type":"pipeline","source":"Citeline News & Insights","summary":"Intercept Withdraws Ocaliva From US, The Last Market For The PBC Drug - Citeline News & Insights","headline":"Intercept Withdraws Ocaliva From US, The Last Market For The PBC Drug - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPMHhROTZMX2EwRnRIdWI2bTlxQW8wbWtxUU9NalRrRG1fclVDa1lMcVl2RzIwWjkwa3lyR2t0Q0dRbU80UkNQX2pCMU5GeGExNmxBRWlzWUZodGc4a0RILWNCQjQ2M0hFVUlkVlFzNVJKNTdYb2x6ZGN3bkhwR0Eya2wtLWdNVWxPRlRPVFhGRjJUYVE5WVNEZHVVY0pReFV5MGNvV05ESkpKSzJCS3k2X2pyN0pxZzQxNHhHMkZSSFV2eVpiazBN?oc=5","date":"2025-09-11","type":"pipeline","source":"Fierce Pharma","summary":"Intercept, after many setbacks, pulls liver disease drug Ocaliva in US - Fierce Pharma","headline":"Intercept, after many setbacks, pulls liver disease drug Ocaliva in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPVEVGSmdfbmxZeUREdUVCXzFmSkt1eGNMdk54M2NzckpEWjJyQ0c0RnpxVnFSS2R3X3pPWXdTS1NCdkZHUk1tdFk1aU51SkdPSzBXQjBWdDU2amtyT2tJNmdGdVUtSVJjNDM4ZmdoN2pQZW02UnFRS3NrNFVzVlRKR1lGZmdxcTcwU2FFbzRIeDVzZHEzSF9IV2RpUTlvS0o1UWJqX1FTSjlIR2htSHZhRVVSM3lTdw?oc=5","date":"2024-11-13","type":"regulatory","source":"Pharmaceutical Technology","summary":"Intercept loses Ocaliva FDA full approval bid in rare liver disease - Pharmaceutical Technology","headline":"Intercept loses Ocaliva FDA full approval bid in rare liver disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQWU5xbjB2d0Q4RU9tNmh5ellDQjk5bGNHdXFVdmNHTG5pVF9JRVFrM0wtNWZRSkx2X21FbXhMMTYyQnA1SWpkYy1vUDBYMG05OWtId0RMNTlSTnZaQ0lKZTE1MzNRYUp1U3Q0UTdTSWxkSm9WTjNzN1E5YkJJWlpKQThIWGRRMXk1Z203RDEyY21zUFN1UU51S1pXUQ?oc=5","date":"2023-09-26","type":"deal","source":"BioSpace","summary":"Alfasigma Buys Beleaguered Intercept Pharmaceuticals in $800M Cash Deal - BioSpace","headline":"Alfasigma Buys Beleaguered Intercept Pharmaceuticals in $800M Cash Deal","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":130956000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":130956000,"period":"2017-12-31"},{"value":37687000,"period":"2017-12-31"},{"value":41334000,"period":"2017-09-30"},{"value":30887000,"period":"2017-06-30"},{"value":21048000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":176639000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":221816000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":553711000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}